

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/693233
				Filing Date	October 24, 2003
				First Named Inventor	KAYMAKCALAN, Zehra
				Art Unit	1644
Examiner Name	SKELDING, ZACHARY S.				
Attorney Docket Number	BBI-190RCE				
Sheet	1	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US5998378	12-07-1999	Kriegler	
	A2	US6267958	7-31-2001	Andya et al.	
	A3	US5237054	08-17-1993	Brinks et al.	
	A4	US4897465	01-30-1990	Cordle et al.	
	A5	US7141542	11-28-2006	Cowan et al.	
	A6	US5608038	04-03-1997	Eibl et al.	
	A7	US6165467	12-26-2000	Hagiwara et al.	
	A8	US6485725	11-26-2006	Hirao et al.	
	A9	US7220409	05-22-200	Norman et al.	
	A10	US7318931	01-15-2008	Okumu et al.	
	A11	US6737405	05-18-2004	Roemisch et al.	
	A12	US6818613	11-16-2004	Sharma et al.	
	A13	US5654403	08-05-1997	Smith et al.	
	A14	US5792838	08-11-1998	Smith et al.	
	A15	US4597966	07-01-1986	Zolton et al.	
	A16	US2006/0127395	06-15-2006	Arvinte et al.	
	A17	US2007/0243185	10-18-2007	Gombotz et al.	
	A18	US2004/0156835	08-12-2004	Imoto et al.	
	A19	US2003/0138417	07-24-2003	Kaisheva et al.	
	A20	US2003/0190316	10-09-2003	Kakuta et al.	
	A21	US2005/0214278	09-29-2005	Kakuta et al.	
	A22	US2005/0118163	06-02-2005	Mizushima et al.	
	A23	US2005/0118167	06-02-2005	Okada et al.	
	A24	US2004/0038878	02-26-2004	Tanikawa et al.	
	A25	US2004/0213785	10-28-2004	Yamazaki et al.	
	A26	US2006/0182740	08-17-2006	Yang et al.	
	A27	US7223394	05-29-2007	Salfeld et al.	
	A28	US7541031	06-02-2009	Salfeld et al.	
	A29	US7588761	09-15-2009	Salfeld et al.	
	A30	US2010/0016557 A1	01-21-2010	Salfeld et al.	
	A31	US2009/0155205 A1	06-18-2009	Salfeld et al.	
	A32	US2003/0235585 A1	12-25-2003	Fischkoff et al.	
	A33	US2004/0033228 A1	02-19-2004	Krause et al.	
	A34	US2006/0153846 A1	07-13-2006	Krause et al.	
	A35	US2003/0206898 A1	11-06-2003	Fischkoff et al.	
	A36	US2004/0009172 A1	01-15-2004	Fischkoff et al.	
	A37	US2004/0166111 A1	08-26-2004	Kaymakcalan et al.	
	A38	US2006/0009385 A1	01-12-2006	Hoffman et al.	
	A39	US2009/0304682 A1	12-10-2009	Hoffman et al.	
	A40	US2006/0083741 A1	04-20-2006	Hoffman et al.	
	A41	US2007/0041905 A1	02-22-2007	Hoffman et al.	
	A42	US2007/0081996 A1	04-12-2007	Hoffman et al.	
	A43	US2007/0071747 A1	03-29-2007	Hoffman et al.	
	A44	US2007/0172897 A1	07-26-2007	Maksymowych et al.	
	A45	US2007/0292442 A1	12-20-2007	Wan et al.	
	A46	US2009/0110679 A1	04-30-2009	Li et al.	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/693233
				Filing Date	October 24, 2003
				First Named Inventor	KAYMAKCALAN, Zehra
				Art Unit	1644
				Examiner Name	SKELDING, ZACHARY S.
Sheet	2	of	3	Attorney Docket Number	BBI-190RCE

A47	US2009/0291062 A1	11-26-2009	Fraunhofer et al.	
A48	US2008/0166348 A1	07-10-2008	Kupper et al.	
A49	US2009/0028794 A1	01-29-2009	Medich et al.	
A50	US2009/0317399 A1	12-24-2009	Pollack et al.	
A51	US2008/0118496 A1	05-22-2008	Medich et al.	
A52	US2009/0123378 A1	05-14-2009	Wong et al.	
A53	US2008/0131374 A1	06-05-2008	Medich et al.	
A54	US2008/0311043 A1	12-18-2008	Hoffman et al.	
A55	US2010/0021451 A1	01-28-2010	Wong et al.	
A56	US2009/0017472 A1	01-15-2009	Stuhlmuller et al.	
A57	US2009/0258018 A1	10-15-2009	Medich et al.	
A58	US2008/0227136 A1	09-18-2008	Pla et al.	
A59	US2009/0239259 A1	09-24-2009	Hsieh et al.	
A60	US2009/0226530 A1	09-10-2009	Lassner et al.	
A61	US2009/0271164 A1	10-29-2009	Peng et al.	
A62	US2010/0003243 A1	01-07-2010	Okun et al.	
A63	US2004/0126372 A1	07-01-2004	Banerjee et al.	
A64	US2007/0202104 A1	08-30-2007	Banerjee et al.	
A65	US2004/0131614 A1	07-08-2004	Banerjee et al.	
A66	US2004/0126373 A1	07-01-2004	Banerjee et al.	
A67	US2004/0151722 A1	08-05-2004	Banerjee et al.	
A68	US2004/0136991 A1	07-08-2004	Banerjee et al.	
A69	US2008/0193466 A1	08-14-2008	Banerjee et al.	
A70	US2004/0136990 A1	07-15-2004	Banerjee et al.	
A71	US2004/0219142 A1	11-04-2004	Banerjee et al.	
A72	US2004/0136989 A1	07-15-2004	Banerjee et al.	
A73	US2003/0012786 A1	01-16-2003	Teoh et al.	
A74	US2003/0161828 A1	08-28-2003	Abdelghany et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	B1	EP 0486526 A1		05-27-1992	Peptide technol. Ltd.		
	B2	WO 01/94585		12-13-2001	Celltech R&D Ltd.		
	B3	EP0929578		5-2-2003	BASF AG		
	B4	WO 01/60420		08-23-2001	Aeropharm Technology, Inc		
	B5	WO 02/072636		09-19-2002	Altus Biologics, Inc.		
	B6	WO 99/37329		07-29-1999	Astra Aktiebolag		
	B7	WO 90/01191		02-08-1990	BMC Software, Inc.		
	B8	WO 98/44948		10-15-1998	Cangene Corporation		
	B9	EP 417191		10-03-1993	Centcor, Inc.		
	B10	WO 00/67798		11-16-2000	CSL Limited		
	B11	WO 03/066681		08-14-2003	Delta Biotechnology Ltd.		
	B12	WO 97/45140		12-04-1997	Glaxo Group Ltd.		
	B13	WO 02/64166		08-22-2002	Korea Inst. for Science		
	B14	WO 04/007520		01-22-2004	Medarex, Inc.		
	B15	EP 419251		01-09-1993	Mitsui Toatsu Chemicals		

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/693233
				Filing Date	October 24, 2003
				First Named Inventor	KAYMAKCALAN, Zehra
				Art Unit	1644
				Examiner Name	SKELDING, ZACHARY S.
Sheet	3	of	3	Attorney Docket Number	BBI-190RCE

	B16	WO 95/03826	02-09-1995	Pasteur Merieux Serums		
	B17	WO 03/009817	02-06-2003	Protein Design Labs, Inc.		
	B18	WO 96/07429	03-14-1996	Red Cross Foundation		
	B19	WO 93/08837	05-13-1993	The Wellcome Foundation		
	B20	WO 00/50079	08-31-2000	Tobinick E.L.		
	B21	WO 02/80891	10-17-2002	A+ Science Invest AB		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	RAU et al, Experiences with D2E7, Aktuelle Rheumatologie 25(3): 83-88, 2000. [English Translation]			
	C2	KEFFER et al., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10(13): 4025-4031, 1991.			
	C3	TAYLOR et al., Anti-tumor necrosis factor therapies. Curr. Opin. Rheumatol. 13(3): 164-169, 2001.			
	C4	ZHOU et al., [New drugs for treating Rheumatoid Arthritis] (Chinese). China Pharmacist 2(2): 109, 1999.			
	C5	LORENZ et al., Perspectives for TNFalpha-targeting therapies. Arthritis Research 4(Suppl 3): S17-S24, 2002.			
	C6	LORENZ, "Biologocal Agents: a novel approach to the therapy of rheumatoid arthritis", Expert opinion on investigational drugs, Ashley Publications Ltd. London, GB Vol. 9, No 7, 2000, pages 1479-1490, ISSN: 1354-3784.			
	C7	LOVELL et al., Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis and Rheumatism 48(1): 218-226, 2003.			
	C8	PENNINGTON et al., Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect. Immun. 54: 239-244, 1986.			
	C9	SHIMOZATO et al., Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect. Immun. 58: 1384-1390, 1990.			
	C10	SIVASAI et al., Cytomegalovirus immune globulin intravenous (human) administration. Clin. Exp. Immunol. 119: 559-565, 2000.			
	C11	Medline Plus Arthritis Actualizado 02-02-2002.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--